RESUMEN
alpha-thalassemia was sought by gene mapping in 258 subjects selected on the basis of origin (25%), microcytosis (7%), or origin and microcytosis combined (64%). Abnormal fragments (Xba I/probe alpha) were found in 58 cases (22.5%). Using other restriction enzymes it was possible to determine the genotype alpha-/aa in 39 patients and the genotype alpha-/alpha- in 13 patients; 2 patients also exhibited hemoglobin H (alpha-/--) disease. alpha triplication anti-3.7 kb was found in 2 subjects and zeta-thalassemia in 2 other samples. 57 out of 58 patients originated from the thalassemia belt or from Africa. alpha-thalassemia is the most frequent hemoglobinopathy (21% of patients at risk) and hematologically is characterized by microcytosis. The Hb A2 level is decreased only in the alpha-/-- form of the disease. The main advantage of diagnosing zeta-thalassemias and alpha triplications lies in the possible clinical implications in the event of association with other hemoglobinopathies or beta-thalassemia.
Asunto(s)
Mapeo Restrictivo , Talasemia/genética , Diagnóstico Diferencial , Femenino , Genotipo , Hemoglobina A2/análisis , Hemoglobina H/análisis , Hemoglobinopatías/diagnóstico , Humanos , Masculino , Talasemia/diagnósticoRESUMEN
The study evaluates three enzyme-linked immunosorbent assays (ELISA) of malaria antigens suitable for use in large-scale epidemiological studies. Results obtained using sera from 567 persons from the Gambia indicated that the micro-ELISA method using parasitized red blood cell extract did not reliably quantitate antimalarial antibodies, especially in young children. In contrast, two micro-ELISA methods that employed purified, defined antigens (a polypeptide of M(r) = 41 000 present in rhoptries, and a 31-1 fusion polypeptide corresponding to a merozoite surface antigen) permitted the precise determination of antimalarial antibodies in both adults and children. Problems and advantages associated with the use of the M(r) = 41 000 and 31-1 antigens for the determination of antimalarial antibodies are discussed.